Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Congenital myasthenic syndrome with episodic apnoea: clinical, neurophysiological and genetic features in the long-term follow-up of 19 patients

Lookup NU author(s): Dr Grace McMacken, Professor Roger Whittaker, Dr Teresinha Evangelista, Professor Hanns Lochmuller

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2017 The Author(s) Background: Congenital myasthenic syndrome with episodic apnoea (CMS-EA) is a rare but potentially treatable cause of apparent life-threatening events in infancy. The underlying mechanisms for sudden and recurrent episodesof respiratory arrest in these patients are unclear. Whilst CMS-EA is most commonly caused by mutations in CHAT, the list of associated genotypes is expanding. Methods: We reviewed clinical information from 19 patients with CMS-EA, including patients with mutations in CHAT, SLC5A7 and RAPSN, and patients lacking a genetic diagnosis. Results: Lack of genetic diagnosis was more common in CMS-EA than in CMS without EA (56% n = 18, compared to 7% n = 97). Most patients manifested intermittent apnoea in the first 4 months of life (74%, n = 14). A degree of clinical improvement with medication was observed in most patients (74%, n = 14), but the majority of cases also showed a tendency towards complete remission of apnoeic events with age (mean age of resolution 2 years 5 months). Signs of impaired neuromuscular transmission were detected on neurophysiology studies in 79% (n = 15) of cases, but in six cases, this was only apparent following specific neurophysiological testing protocols (prolonged high-frequency stimulation). Conclusions: A relatively large proportion of CMS-EA remains genetically undiagnosed, which suggests the existence of novel causative CMS genes which remain uncharacterised. In light of the potential for recurrent life-threatening apnoeas in early life and the positive response to therapy, early diagnostic consideration of CMS-EA is critical, but without specific neurophysiology tests, it may go overlooked.


Publication metadata

Author(s): McMacken G, Whittaker RG, Evangelista T, Abicht A, Dusl M, Lochmuller H

Publication type: Article

Publication status: Published

Journal: Journal of Neurology

Year: 2018

Volume: 265

Issue: 1

Pages: 194-203

Print publication date: 01/01/2018

Online publication date: 30/11/2017

Acceptance date: 20/11/2017

Date deposited: 14/12/2017

ISSN (print): 0340-5354

ISSN (electronic): 1432-1459

Publisher: Springer Berlin Heidelberg

URL: https://doi.org/10.1007/s00415-017-8689-3

DOI: 10.1007/s00415-017-8689-3


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
98482
G1002274
MRC

Share